Papers by Françoise Mornex
European Journal of Cancer Supplements, 2007
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2010
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2009
Bookmarks Related papers MentionsView impact
International Journal of Radiation Oncology*Biology*Physics, 2007
Bookmarks Related papers MentionsView impact
International Journal of Radiation Oncology Biology Physics, 2005
Purpose: This retrospective 12-year study evaluated the prognostic value of initial and postopera... more Purpose: This retrospective 12-year study evaluated the prognostic value of initial and postoperative staging of rectal tumors. Methods and Materials: Between 1985 and 1996, 297 patients were treated with preoperative radiotherapy (39 Gy in 13 fractions) and surgery for Stage T2-T4N0-N1M0 rectal adenocarcinoma. Pretreatment staging included a clinical examination and endorectal ultrasonography (EUS) since 1988. Clinical staging was performed by
Bookmarks Related papers MentionsView impact
Seminars in Radiation Oncology, 1998
Bookmarks Related papers MentionsView impact
Cancer, 1984
Bookmarks Related papers MentionsView impact
International Journal of Radiation OncologyBiologyPhysics
To evaluate whether the tumor response after an initial course of irradiation predicts for colost... more To evaluate whether the tumor response after an initial course of irradiation predicts for colostomy-free survival and overall survival in patients with anal canal cancer. Between 1980 and 1998, 252 patients were treated by pelvic external-beam radiotherapy (EBRT) followed by a brachytherapy boost in 218 or EBRT in 34. EBRT was combined with chemotherapy in 168 patients. An evaluation of tumor regression, before the boost, was available for 221 patients. They were divided into four groups according to the tumor response: <70%, 70-80%, >80% but <100%, and 100%. The median follow-up time was 58 months. The overall survival rate was 72.6% +/- 3.1% and 57.3% +/- 4.2% at 5 and 10 years, respectively. The disease-free survival rate was 60.0% +/- 3.3% and 49.4% +/- 3.9% at 5 and 10 years, respectively. The colostomy-free survival rate was 61% at 5 years and 47% at 10 years. Two groups could be differentiated according to the percentage of tumor regression before the boost: >80%...
Bookmarks Related papers MentionsView impact
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique, 2011
Medical therapies for hepatocellular carcinoma are limited. Standard antimitotic chemotherapies a... more Medical therapies for hepatocellular carcinoma are limited. Standard antimitotic chemotherapies and hormonotherapies are inefficient. Only sorafenib, an antiangiogenic agent inhibiting the VEGF and PDGF receptors as well as MAP kinase pathway, has shown a significant benefit on patient survival. However, its indication is restricted to patients with multifocal hepatocellular carcinoma not responding to transarterial hepatic chemoembolization or patients with hepatocellular carcinoma invading the venous portal tract or spreading to lymph nodes or as distant visceral metastasis.
Bookmarks Related papers MentionsView impact
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique, 2011
Hepatocellular carcinoma is a poor prognosis tumour. The potential curative therapeutic options a... more Hepatocellular carcinoma is a poor prognosis tumour. The potential curative therapeutic options are orthotopic liver transplantation, surgical resection and radiofrequency ablation. Unfortunately, only a minority of patients (around 20%) are eligible for these techniques. Thus, patients can benefit from palliative options, such as transarterial chemoembolization (TACE) or sorafenib that bring only modest benefit on survival. Conformal radiotherapy allows delivering high dose radiation within a precise tumour volume while sparing the surrounding liver parenchyma. As employed in monotherapy, conformal radiotherapy is highly efficient for small size hepatocellular carcinoma (<5 cm). Above 5 cm, its efficacy is more limited but its association with TACE gives spectacular rates of complete responses. Controlled phase 2 or 3 trials are urgently warranted to define its indications in the therapeutic algorithm of hepatocellular carcinoma.
Bookmarks Related papers MentionsView impact
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique, 2011
Several phase II studies have shown the feasibility of neoadjuvant chemoradiation regimens for re... more Several phase II studies have shown the feasibility of neoadjuvant chemoradiation regimens for resectable localized pancreatic adenocarcinoma. However, there is to date no completed phase III study to validate this approach and treatment effects evaluation still remains an active area of investigation. From the mature results of the SFRO-FFCD 9704 trial, we explored the antitumoral effect of a 5-fluoro-uracil and cisplatin-based preoperative chemoradiation regimen, with a special highlight on the histopathological response and performed a literature review. Treatment consisted of concurrent radiotherapy (50 Gy within five weeks) and chemotherapy with 5-fluoro-uracil (300 mg/m(2)/day, five days/week, weeks 1-5) and cisplatin (20mg/m(2)/day, days 1-5 and 29-33), followed by surgical resection of the pancreatic tumour in patients without progression. In all, 41 patients were enrolled, 26 patients (63%) underwent surgical resection with curative intent and 21 (80.7%) had R0 resection. A...
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2008
Bookmarks Related papers MentionsView impact
Digestive and Liver Disease, 2014
We performed a randomized, non-comparative phase II study evaluating docetaxel in combination wit... more We performed a randomized, non-comparative phase II study evaluating docetaxel in combination with either daily continuous (protracted IV) 5-fluorouracil or cisplatin administered weekly, concurrent to radiotherapy in the treatment of locally advanced pancreatic carcinoma. Results of the docetaxel plus cisplatin regimen are reported. Forty chemotherapy-naive patients with locally advanced pancreatic carcinoma were randomly assigned to receive 5-fluorouracil and docetaxel or docetaxel 20mg/m(2) and cisplatin 20mg/m(2)/week, plus concurrent radiotherapy for 6 weeks. The radiation dose to the primary tumour was 54Gy in 30 fractions. The trial&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s primary endpoint was the 6-month crude non-progression rate. 51 patients from 7 centres were included in the docetaxel-cisplatin treatment group. Six-month non-progression rate was 39% (95% confidence interval: 26-53). Median overall survival was 9.6 months (95% confidence interval: 2.4-60.7); 6 complete and 8 partial responses were obtained. Six patients survived more than 2 years after their inclusion in the trial. Grade ≥3 toxicity was reported in 63% of patients; no treatment-related death occurred. Severe toxicities were mainly anorexia (22%), vomiting (20%) and fatigue (24%). Despite inadequate efficacy according to the main end point, this regimen gave a satisfactory rate of objective response (27%) with tolerable toxicity.
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
Bookmarks Related papers MentionsView impact
More than 80% of patients who undergo a potentially curative resection for pancreatic cancer deve... more More than 80% of patients who undergo a potentially curative resection for pancreatic cancer develop local or distant recurrence. Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation. Treatment consisted of concurrent radiotherapy (50 Gy within 5 weeks), and chemotherapy with 5-fluorouracil (300 mg/m(2)/day, 5 days/week, 5 consecutive weeks) and cisplatin (20 mg/m(2)/day, Days 1-5 and 29-33), followed by surgical resection of the pancreatic tumor in patients without progression. A total of 41 patients were enrolled. Of these, 38 (93%) received &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt; or =47 Gy; 30 patients (73%) received &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt; or =75% of the prescribed doses of chemotherapy. Surgical resection was performed in 26 patients (63%). Because of local or metastatic progression, 5 patients (12%) did not undergo surgery and 10 underwent surgery without resection of the pancreatic tumor. Operative mortality was 2.8%. Among 40 evaluable patients, 27 were successfully treated (67.5%; 95% CI, 50.9-81.4%). Pancreatic cancer is chemo-radiosensitive. The proposed pre-operative scheme is feasible, does not prevent successful surgery, and must be tested on a Phase III setting. Yet, the large proportion of tumor progression during and after chemoradiation justifies the use of more efficient drugs such as Gemcitabine, and optimized radiotherapy including new techniques such as intensity-modulated radiation therapy.
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 1997
... Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (63). M Blichert-Toft, H ... more ... Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (63). M Blichert-Toft, H Brincker, JA Andersen, KW Andersen, CK Axelsson and HT Mouridsen et al., A danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. ...
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2009
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2009
Bookmarks Related papers MentionsView impact
Cancer/Radiothérapie, 2007
Bookmarks Related papers MentionsView impact
Uploads
Papers by Françoise Mornex